Mesa Laboratories Inc

Mesa Laboratories Inc(MLAB)股票分析

$129.090

+0.439 (+0.34%)收盤時

Loading chart…
High
129.660
Open
127.810
VWAP
128.51
Vol
153.08K
Mkt Cap
458.17M
Low
126.790
Amount
19.67M
EV/EBITDA, TTM
25.27

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.

mesalabs.com

AI analysis of Mesa Laboratories Inc (MLAB)

buy

Mesa Laboratories Inc is a good buy right now due to its recent price increase of 3.47% over the last five days and a strong gross margin of 66.23% in Q4 2026, which suggests robust profitability. The current RSI of 83.95 indicates strong momentum, although it is approaching overbought territory. The main risk is the recent earnings miss, where revenue fell short by approximately $1.48 million, leading to a significant stock price drop of 19.5% following the Q4 report.

Analyst Ratings (2)

-23.31% downside
Buy
1 Buy
1 Hold
0 Sell
Current: 129.09
最低
83.00
平均
99.00
最高
115.00

Wells Fargo

2026-02-04

目標價

$94

Equal Weight

Wells Fargo

2025-12-15

目標價

$83

Equal Weight

Jefferies

2025-11-07

目標價

$115

Buy

Wells Fargo

2025-08-07

目標價

$67

Equal Weight

Wells Fargo

2025-05-30

目標價

$100

Underweight

估值指標

The current forward P/E ratio for Mesa Laboratories Inc (MLAB) is 35.21, compared to its 5-year average forward P/E of 30.52.

Forward P/E

Fair
5Y Average P/E
30.52
Current P/E
35.21
高估
45.88
低估
15.15

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
18.89
Current EV/EBITDA
25.27
高估
28.62
低估
9.16

Forward P/S

Fair
5Y Average P/S
3.41
Current P/S
2.66
高估
5.20
低估
1.62

Alphio AI Price Scenarios for MLAB

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MLAB

$100.37

情境價格

B

Base

Base · 50%MLAB

$97.94

情境價格

B

Bear

Bear · 25%MLAB

$84.63

情境價格

Whales holding MLAB

R

Ranger Investment Management, L.P.

+ HoldingMLAB

-4.23%

3M Return

事件時間軸

2026-08-10 (ET)

16:30:00

Mesa Q1 Revenue at $60.14M, Below Consensus

2026-05-27 (ET)

08:10:00

Mesa Q1 Revenue at $63.72M, Below Consensus

2026-03-09 (ET)

16:40:00

Mesa Labs Appoints Siddhartha Kadia as New CEO

2026-02-03 (ET)

08:10:00

Mesa Reports Q3 Revenue of $65.126M, Beating Consensus

2025-11-06 (ET)

16:44:20

Mesa Labs announces Q2 earnings per share of 45 cents, down from 63 cents a year ago.

資訊

MLAB FAQ — answered by Alphio AI

Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).

Mesa Laboratories Inc is a good buy right now due to its recent price increase of 3.47% over the last five days and a strong gross margin of 66.23% in Q4 2026, which suggests robust profitability. The current RSI of 83.95 indicates strong momentum, although it is approaching overbought territory. The main risk is the recent earnings miss, where revenue fell short by approximately $1.48 million, leading to a significant stock price drop of 19.5% following the Q4 report.

2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始